Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924310 | 0.89 | MAPT (0.69) | MAPTRAB9APTGS2MKNK1EGFR | |
| SCHEMBL922804 | 0.89 | MKNK1 (0.66) | MAPTRAB9APTGS2MKNK1EGFR | |
| SCHEMBL923231 | 0.87 | MKNK1 (0.67) | MAPTRAB9APTGS2MKNK1EGFR | |
| SCHEMBL922886 | 0.87 | MAPT (0.50) | MAPTRAB9APTGS2MKNK1EGFR | |
| SCHEMBL923249 | 0.87 | MAPT (0.50) | MAPTRAB9APTGS2MKNK1EGFR | |
| SCHEMBL923542 | 0.85 | PTGS2 (0.60) | MAPTRAB9APTGS2MKNK1EGFR | |
| SCHEMBL924123 | 0.80 | MKNK1 (0.77) | MAPTMKNK1EGFRMAPK1LMNA | |
| SCHEMBL922575 | 0.69 | RAB9A (0.57) | MAPTRAB9ALMNAHTTHPGD | |
| SCHEMBL8179180 | 0.69 | PDE5A (0.54) | MAPTRAB9APTGS2GAALMNA | |
| Bicarbonate SCHEMBL7015314 | 0.68 | PDE5A (0.59) | MAPTRAB9APTGS2GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802849-B2 | Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-08-12 | — | — | US | claimed |
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATO KFT. (HU) | 2011-01-20 | — | — | US | claimed |
| US-8802849-B2 | Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-08-12 | — | — | US | disclosed |
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATO KFT. (HU) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | TYMS, TYMP, DPYD | MAPT 3085/4885RAB9A 2986/4885PTGS2 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.